H1N1 Vaccine in Pregnant Women

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00963430
First received: August 20, 2009
Last updated: November 29, 2012
Last verified: April 2010
Results First Received: April 21, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator, Outcomes Assessor);   Primary Purpose: Prevention
Condition: Influenza
Intervention: Biological: Inactivated H1N1 Vaccine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were healthy pregnant women recruited from existing volunteer populations and from the communities at large around the clinical sites. Participants were enrolled between 09Sep2009 and 16Oct2009.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
15 Mcg H1N1 Vaccine Participants received 15 mcg of Inactivated H1N1 Vaccine by intramuscular injection on Day 0 and Day 21.
30 Mcg H1N1 Vaccine Participants received 30 mcg of Inactivated H1N1 Vaccine by intramuscular injection on Day 0 and Day 21.

Participant Flow:   Overall Study
    15 Mcg H1N1 Vaccine     30 Mcg H1N1 Vaccine  
STARTED     60     60  
COMPLETED     59     57  
NOT COMPLETED     1     3  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
15 Mcg H1N1 Vaccine Participants received 15 mcg of Inactivated H1N1 Vaccine by intramuscular injection on Day 0 and Day 21.
30 Mcg H1N1 Vaccine Participants received 30 mcg of Inactivated H1N1 Vaccine by intramuscular injection on Day 0 and Day 21.
Total Total of all reporting groups

Baseline Measures
    15 Mcg H1N1 Vaccine     30 Mcg H1N1 Vaccine     Total  
Number of Participants  
[units: participants]
  60     60     120  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     60     60     120  
>=65 years     0     0     0  
Age  
[units: years]
Mean ± Standard Deviation
  31.7  ± 4.3     31.2  ± 4.3     31.4  ± 4.3  
Gender  
[units: participants]
     
Female     60     60     120  
Male     0     0     0  
Region of Enrollment  
[units: participants]
     
United States     60     60     120  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants Reporting Solicited Subjective Local Reactions After First Vaccination   [ Time Frame: Within 8 days (Day 0-7) post first vaccination ]

2.  Primary:   Number of Participants Reporting Solicited Subjective Local Reactions After Second Vaccination   [ Time Frame: Within 8 days (Day 0-7) post second vaccination ]

3.  Primary:   Number of Participants Reporting Solicited Quantitative Local Reactions After First Vaccination   [ Time Frame: Within 8 days (Day 0-7) post first vaccination ]

4.  Primary:   Number of Participants Reporting Solicited Quantitative Local Reactions After Second Vaccination   [ Time Frame: Within 8 days (Day 0-7) post second vaccination ]
  Hide Outcome Measure 4

Measure Type Primary
Measure Title Number of Participants Reporting Solicited Quantitative Local Reactions After Second Vaccination
Measure Description Participants maintained a memory aid to record daily the occurrence of local reactions of redness and swelling for 8 days after vaccination (Day 0-7). If the reaction was present, the maximum diameter was measured in millimeters (mm). Participants are counted if they reported experiencing the reaction with any measurement greater than 0 mm on any of the 8 days.
Time Frame Within 8 days (Day 0-7) post second vaccination  
Safety Issue Yes  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All participants receiving the second vaccination are included in the safety cohort. Analyses are as treated.

Reporting Groups
  Description
15 Mcg H1N1 Vaccine Participants received 15 mcg of Inactivated H1N1 Vaccine by intramuscular injection on Day 0 and Day 21.
30 Mcg H1N1 Vaccine Participants received 30 mcg of Inactivated H1N1 Vaccine by intramuscular injection on Day 0 and Day 21.

Measured Values
    15 Mcg H1N1 Vaccine     30 Mcg H1N1 Vaccine  
Number of Participants Analyzed  
[units: participants]
  49     54  
Number of Participants Reporting Solicited Quantitative Local Reactions After Second Vaccination  
[units: Participants]
   
Redness     2     3  
Swelling     1     0  

No statistical analysis provided for Number of Participants Reporting Solicited Quantitative Local Reactions After Second Vaccination



5.  Primary:   Number of Participants Reporting Solicited Subjective Systemic Reactions After First Vaccination   [ Time Frame: Within 8 days (Day 0-7) post first vaccination ]

6.  Primary:   Number of Participants Reporting Solicited Subjective Systemic Reactions After Second Vaccination   [ Time Frame: Within 8 days (Day 0-7) post second vaccination ]

7.  Primary:   Number of Participants Reporting Fever After First Vaccination   [ Time Frame: Within 8 days (Day 0-7) post first vaccination ]

8.  Primary:   Number of Participants Reporting Fever After Second Vaccination   [ Time Frame: Within 8 days (Day 0-7) post second vaccination ]

9.  Primary:   Number of Participants With 4-fold or Greater Serum Hemagglutination Inhibition (HAI) Antibody Titer Increases Against Influenza H1N1 2009 Virus Following a Single Dose of H1N1 Vaccine   [ Time Frame: Day 0 prior to and Day 21 after the first vaccination ]

10.  Primary:   Number of Participants With a Serum Hemagglutination Inhibition (HAI) Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus Following a Single Dose of H1N1 Vaccine   [ Time Frame: Day 21 after the first vaccination ]

11.  Primary:   Number of Participants Reporting Maternal Complications of Pregnancy, Labor and Delivery   [ Time Frame: At time of delivery ]

12.  Primary:   Number of Participants Reporting Neonatal Complications   [ Time Frame: At time of delivery ]

13.  Primary:   Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs)   [ Time Frame: Day 0 through Day 180 after last vaccination ]

14.  Secondary:   Number of Participants With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer Greater Than or Equal to 40 Against the Novel Influenza H1N1 2009 Virus in the Maternal Blood at the Time of Delivery   [ Time Frame: At time of delivery ]

15.  Secondary:   Number of Participants With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer Greater Than or Equal to 40 Against the Novel Influenza H1N1 2009 Virus in Cord Blood   [ Time Frame: At time of delivery ]

16.  Secondary:   Number of Participants With 4-fold or Greater Serum Hemagglutination Inhibition (HAI) Antibody Titer Increases Against Influenza H1N1 2009 Virus Following 2 Doses of H1N1 Vaccine   [ Time Frame: Day 0 prior to first vaccination and Day 21 after the second vaccination ]

17.  Secondary:   Number of Participants With a Serum Hemagglutination Inhibition (HAI) Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus Following 2 Doses of H1N1 Vaccine   [ Time Frame: Day 21 after the second vaccination ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information